Abstract Number: 1361 • 2018 ACR/ARHP Annual Meeting
Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
Background/Purpose: Phenotype identification in knee osteoarthritis (KOA) population could be useful for predicting drug response, allowing personalized interventions. In order to optimize therapeutic outcome in…Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…Abstract Number: 1203 • 2017 ACR/ARHP Annual Meeting
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Background/Purpose: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, including osteoarthritis (OA), but are associated with adverse effects. Combined glucosamine hydrochloride plus…Abstract Number: 1208 • 2017 ACR/ARHP Annual Meeting
Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Background/Purpose: There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in…Abstract Number: 2231 • 2014 ACR/ARHP Annual Meeting
Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL
Background/Purpose The Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) compared efficacy and safety of Chondroitin sulfate (CS) and Glucosamine Hydrochloride (GH) with that of Celecoxib…Abstract Number: 2250 • 2014 ACR/ARHP Annual Meeting
The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort
Background/Purpose: In the perspective of personalized management of osteoarthritis (OA), a clinically relevant concern is the impact of meniscal extrusion on response to treatment. This study evaluated the role…Abstract Number: 858 • 2013 ACR/ARHP Annual Meeting
Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is characterized by acute episodes of joint pain. Monosodium urate (MSU) crystals…Abstract Number: 169 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On The Gene Expression Profile In Interleukin-1β Stimulated Synovial Fibroblast Cells Cultures
Background/Purpose: Chondroitin sulfate (CS) is one the most used molecules in the management of OA. Its mechanism of action remains to be detailed. In this…Abstract Number: 171 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On The Gene Expression Profile In The Inflamed Synovial Membrane
Background/Purpose: Chondroitin sulfate (CS) is one the most used molecules in the management of OA. Its mechanism of action remains to be detailed. The aim…Abstract Number: 2145 • 2013 ACR/ARHP Annual Meeting
Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort
Background/Purpose: To explore, using data from participants enrolled in the progression cohort of the Osteoarthritis Initiative (OAI), the effects of conventional knee osteoarthritis (OA) pharmacological…Abstract Number: 2146 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On Brain Response To Painful Stimulation In Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Background/Purpose: Knee osteoarthritis (OA) is a degenerative joint disease causing symptoms in 12% of people over the age of 65 . A variety of treatments…Abstract Number: 2113 • 2013 ACR/ARHP Annual Meeting
Glucosamine–Chondroitin Sulfate Reduces Pain, Disability and Non-Steroidal Anti-Inflammatory Drug consumption In Patients With Chronic Low Back Pain: A Large, Community-Based, Pilot, Open Prospective Study
Background/Purpose: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 identified low back pain as the leading cause of Years Lived with Disability…Abstract Number: 1124 • 2012 ACR/ARHP Annual Meeting
Total Knee Replacement As an Osteoarthritis Study Outcome: Predictors Derived From Long-Term Observation Following a Randomized Clinical Trial
Background/Purpose: Using data from a 4-year follow-up of knee OA patients who formerly received treatment with chondroitin sulfate (CS) within a 6-month clinical trial, we…Abstract Number: 1135 • 2012 ACR/ARHP Annual Meeting
Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis
Background/Purpose: The analgesic efficacy of combined glucosamine and chondroitin sulfate (CS) in knee osteoarthritis (OA) remains controversial. Criticism to previous studies includes small sample size,…Abstract Number: 1101 • 2012 ACR/ARHP Annual Meeting
Condroitin Sulfate Decreases Chemokine Levels and Synovitis in knee osteoarthritis Patients
Background/Purpose: Synovitis is one of the major signs of structure damage in osteoarthritis (OA) progression. Chondroitin sulfate (CS) is an effective drug in the treatment…